Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety
The company's first set of Phase II data for its oral, selective TYK2 inhibitor in psoriasis showed a consistent dose response as well as safety that could rival the related JAK inhibitor class. BMS-986165 already is in Phase III for psoriasis; it's in Phase II for lupus and Crohn's disease.
You may also be interested in...
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Research and early development head Rupert Vessey, who had a similar role at Celgene, told Scrip that integration of the company’s pipeline into Bristol is nearly complete with few overlapping programs.